文献速递口腔黏膜病牙周病

遗传学支持的药物靶点与口腔牙科性状:孟德尔随机化研究

Genetically Supported Drug Targets and Dental Traits: A Mendelian Randomization Study.
PubMed 文献 · J Dent Res · 2024-10-06

本研究利用孟德尔随机化方法,将4,302个可成药基因与31,684份血液样本的eQTL数据取交集,确定2,580个可成药靶点作为暴露,以FinnGen R9、GLIDE联盟和UK Biobank的牙科疾病/症状性状为结局。分析鉴定出43个可成药靶点,其中IL12RB1与TNF对口腔溃疡、CXCL10对牙周炎显示治疗潜力。

要点

  • IL12RB1(OR 1.01,95%CI 1.01-1.01)和TNF(OR 0.98,95%CI 0.97-0.99)对口腔溃疡显示治疗潜力。
  • CXCL10(OR 0.84,95%CI 0.76-0.91)对牙周炎显示治疗潜力。
  • 共鉴定43个可成药靶点,经蛋白QTL重复、共定位及动物模型验证。

核心结论

  • 经严格质控与验证流程,IL12RB1、TNF(口腔溃疡)和CXCL10(牙周炎)等可成药靶点获得有力遗传学证据,有望通过开发新药或老药新用改善临床预后。

研究设计与样本

  • 孟德尔随机化研究;将4,302个可成药基因与31,684份血液样本的eQTL取交集,确定2,580个可成药靶点作为暴露。
  • 结局数据来自FinnGen R9、GLIDE联盟和UK Biobank,用于发现与重复验证。
  • 以循环蛋白QTL作为暴露重复分析,并进行敏感性、共定位、GO/KEGG注释、蛋白互作分析及动物模型表达验证。

主要发现

  • 共鉴定出43个与各类牙科疾病/症状性状相关的可成药靶点。
  • IL12RB1(OR 1.01;95%CI 1.01-1.01)与TNF(OR 0.98;95%CI 0.97-0.99)对口腔溃疡显示治疗潜力。
  • CXCL10(OR 0.84;95%CI 0.76-0.91)对牙周炎显示治疗潜力。

临床怎么用

  • 当前口腔/牙科疾病干预主要依赖手术操作,这些遗传学支持的靶点提示可探索非侵入性药物治疗途径。
  • 可优先关注IL12RB1、TNF与口腔溃疡及CXCL10与牙周炎的潜在药物开发或老药新用方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current interventions for oral/dental diseases heavily rely on operative/surgical procedures, while the discovery of novel drug targets may enable access to noninvasive pharmacotherapy. Therefore, this study aims to leverage large-scale data and Mendelian randomization (MR) techniques, utilizing genetic variants as instruments, to identify potential therapeutic targets for oral and dental diseases supported by genetic evidence. By intersecting 4,302 druggable genes with expression quantitative trait loci from 31,684 blood samples, we identified 2,580 druggable targets as exposures. Single nucleotide polymorphisms associated with dental disease/symptom traits were collected from FinnGen R9, the Gene-Lifestyle Interactions in Dental Endpoints consortium, and the UK Biobank to serve as outcomes for both discovery and replication purposes. Through MR analysis, we identified 43 druggable targets for various dental disease/symptom traits. To evaluate the viability of these targets, we replicated the analysis using circulating protein quantitative trait loci as exposures. Additionally, we conducted sensitivity, colocalization, Gene Ontology/Kyoto Encyclopedia of Genes and Genomes annotation, protein-protein interaction analyses, and validated dental trait-associated druggable gene expression in animal models. Among these targets, IL12RB1 (odds ratio [OR], 1.01; 95% confidence interval [CI], 1.01-1.01) and TNF (OR, 0.98; 95% CI, 0.97-0.99) exhibited therapeutic promise for oral ulcers, whereas CXCL10 (OR, 0.84; 95% CI, 0.76-0.91) was for periodontitis. Through a rigorous quality control and validation pipeline, our study yields compelling evidence for these druggable targets, which may enhance the clinical prognosis by developing novel drugs or repurposing existing ones.

来源:J Dent Res,查看原文。版权归原作者所有。

引用

  1. Liu L, Wang T, Duan C, et al. Genetically Supported Drug Targets and Dental Traits: A Mendelian Randomization Study. J Dent Res. 2024. PMID: 39370703. doi:10.1177/00220345241272045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。